Maintenance Notice (5:30 - 10:30 PM June 28, 2025): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding
Published TCIMAIL newest issue No.198
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 61413-54-5 | Product Number: R0110
Rolipram
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- 4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 50MG |
€110.00
|
1 | 34 |
|
| 250MG |
€382.00
|
1 | 25 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | R0110 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__1__6H__2__1NO__3 = 275.35 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (-20°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 50MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 61413-54-5 |
| Reaxys Registry Number | 1588548 |
| PubChem Substance ID | 253659657 |
| Merck Index (14) | 8251 |
| MDL Number | MFCD00270906 |
Specifications
| Appearance | White to Orange to Green powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Melting point | 130.0 to 134.0 °C |
Properties (reference)
| Melting Point | 132 °C |
GHS
Related Laws:
| EC Number | 262-771-1 |
| RTECS# | UY5749237 |
Transport Information:
| HS Number | 2933790090 |
Application
Rolipram: A Selective PDE4 Inhibitor
Rolipram is a selective inhibitor of phosphodiesterases 4 (PDE4s) originally developed as an antidepressant agent in 1990s, but fell out of favor because of its undesirable gastrointestinal side effects. Nowadays, rolipram continues to be used in research as a PDE4 inhibitor. PDE4s are responsible for hydrolysis of the cyclic nucleotides cAMP [A2381] and cGMP to 5’-AMP [A0158] and 5’-GMP [G0338], particularly in nerve and immune cells. The inhibition of PDE4s by rolipram induces the elevation of intracellular cAMP concentration. Consequences rolipram-induced elevation of cAMP suppress expression of proinflammatory cytokines and other mediators of inflammation. Rolipram has been reported as a drug for the treatment of autoimmune diseases, Alzheimer's disease, cognitive enhancement, and respiratory diseases like asthma and COPD. Rolipram is a racemic compound, and (R)-rolipram [R0182] is more potent than (S)-rolipram [R0183] as a PDE4 inhibitor. (The product is for research purpose only.)
References
- The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
- Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory
- The antidepressant and antiinflammatory effects of rolipram in the central nervous system (a review)
- Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats
- Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment
- Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease (a review)
PubMed Literature
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.